-
公开(公告)号:JP2003201256A
公开(公告)日:2003-07-18
申请号:JP2001399310
申请日:2001-12-28
Applicant: HISAMITSU PHARMACEUTICAL CO
Inventor: SATO HIDEJI , GOTO TAKESHI , TANIDA NOBUFUMI , MEYA TATSUYA , YOSHINAGA TAKAAKI , YONEMURA KEIJI
IPC: A61K47/30 , A61K9/20 , A61K31/513 , A61K31/573 , A61K31/7084 , A61K31/7088 , A61K38/00 , A61K45/00 , A61K47/10 , A61K47/12 , A61K47/16 , A61K47/20 , A61K47/22 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/38 , A61K47/42 , A61K47/46 , A61K48/00 , A61P35/00
Abstract: PROBLEM TO BE SOLVED: To provide a colic delivery oral pharmaceutical preparation, oral pharmaceutical preparation for treatment of colon cancer and oral pharmaceutical preparation for treating colitis which are delivered to the large intestine without causing disintegration in the stomach and the small intestine and starting disintegration in the large intestine and surely finishing disintegration in the large intestine. SOLUTION: This colic delivery oral pharmaceutical preparation comprises an inner layer containing a nuclei containing a pharmacologically active ingredient and one or more kinds of cationic polymers for applying the nuclei and an outer layer containing one or more kinds of anionic polymers. In disintegration test of the preparation comprising vertically moving for 2 hr in a first liquid having pH 1.2 and then vertically moving for 2 hr in a second liquid having pH 7.4 and finally vertically moving in a third liquid having pH 6.4, average disintegration starting time and average disintegration finishing time are designed so as to become a time between 35 min and 130 min after vertical movement in the third liquid is started. COPYRIGHT: (C)2003,JPO
-
公开(公告)号:JPH1033175A
公开(公告)日:1998-02-10
申请号:JP21310196
申请日:1996-07-24
Applicant: HISAMITSU PHARMACEUTICAL CO
Inventor: IIJIMA OSAMU , SATO HIDEJI , SAITO IZUMI , SHIMADA TAKASHI
Abstract: PROBLEM TO BE SOLVED: To obtain the subject vector useful for a gene therapy and in the fields of medicine and biochemistry, etc., by inserting a specific stuffer sequence into an adeno-accompanying virus(AAV) genome sequenpe. SOLUTION: A stuffer sequence held between two recombinase recognition sequences is inserted between a promotor p5 of a helper plasmid derived from a genome of a wild type AAV and a translational initiation codon of rep78/68 gene. The stuffer sequence contains at least one detectable gene marker and a poly-A signal in the same direction as the promotor p5 and the rep78/68 gene. The helper plasmid is subjected to a gene insertion into a 293 cell to obtain a packaging cell for producing a recombinant AAV vector, and a recombinant AAV vector plasmid such as a pNAV and a Cre-expressing plasmid are subjected to a transfection, and an adenovirus is simultaneously infected thereto and then cultured to obtain the objective high-titer recombinant AAV vector.
-
公开(公告)号:JP2003210591A
公开(公告)日:2003-07-29
申请号:JP2002015378
申请日:2002-01-24
Applicant: HISAMITSU PHARMACEUTICAL CO
Inventor: MORI KENJI , TOKUMOTO SEIJI , HIGO SHIGETO , SATO HIDEJI , SUGIBAYASHI KENJI
IPC: A61K9/70 , A61K31/05 , A61K31/155 , A61K31/192 , A61K31/196 , A61K31/375 , A61K47/36 , A61N1/30 , A61P25/04 , A61P39/06 , A61P43/00
Abstract: PROBLEM TO BE SOLVED: To provide a percutaneous transmucosal applying preparation for electroporation in which an administration compound such as a drug can be effectively administered. SOLUTION: The percutaneous transmucosal applying preparation for electroporation has a drug storing layer 11 in which the administration compound (a biologically active substance) such as a drug is dispersed in a base in a solid or semisolid form, a backing 12 for holding the drug storing layer, and a pair of electrodes 13 for electroporation placed on the drug storing layer 11. An adhesive layer 14 is placed in the flange portion of the backing 12. An insulating layer 15 is placed in a part touching at least an applying part except for the upper part of the drug storing layer 11 of the electrode 13 for electroporation. COPYRIGHT: (C)2003,JPO
-
公开(公告)号:JPH09176038A
公开(公告)日:1997-07-08
申请号:JP14959896
申请日:1996-06-11
Applicant: HISAMITSU PHARMACEUTICAL CO , L T T KENKYUSHO KK
Inventor: SATO HIDEJI , GOTO TAKESHI , WADA AKIRA , SUZUKI YOSUKE , KAWAI SHINICHI , MIZUSHIMA YUTAKA
IPC: C12N15/09 , A61K31/70 , A61K38/00 , A61K47/48 , A61K48/00 , A61P1/00 , A61P1/02 , A61P9/10 , A61P13/02 , A61P15/00 , A61P17/00 , A61P29/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P37/04 , A61P43/00 , C07H21/04
Abstract: PROBLEM TO BE SOLVED: To obtain the above medicine comprising the composite product of a synthetic amino acid with a specific antisense oligonucleotide and useful for the therapy of disease states such as inflammatory diseases such as chronic rheumatoid arthritis, septicemia shock and AIDS, etc. SOLUTION: This antiinflammatory antisense medicine comprises the composite product of (A) a synthetic polyamino acid or its derivative with (B) an antisense.oligonucleotide complementary to a part or the whole base sequence of a mRNA coding a physiologically active substance relating to human inflammatory diseases (e.g., human chronic rheumatoid arthritis). The component A is preferably a nucleic acid-bound compound comprising the sequence of repeated lysine and serine residues or a nucleic acid derivative. The derivative of the component A is preferably the polyethylene glycol-blocked product of the synthetic polyamino acid.
-
公开(公告)号:JPH04334326A
公开(公告)日:1992-11-20
申请号:JP13542391
申请日:1991-05-11
Applicant: HISAMITSU PHARMACEUTICAL CO
Inventor: SATO HIDEJI , YAMAGUCHI HISASHI , NOZAWA ITSUKI , KUSUNOKI TAKASANE , NAKAJIMA MIKIO
Abstract: PURPOSE:To obtain the title composition improved in percutaneous absorbability by formulating a specified base with a narcotic or narcotically antagonistic analgesic. CONSTITUTION:The objective composition can be obtained by formulating (A) a base comprised of a lower alcohol, polar solvent and azacycloalkane derivative with (B) as medicinal ingredient, a narcotic or narcotically antagonistic analgesic. The present composition, which has been enhanced in the percutaneous penetrability/permeability for the medicinal ingredient, has significant absorption-promotive activity.
-
公开(公告)号:JPH06199659A
公开(公告)日:1994-07-19
申请号:JP28995292
申请日:1992-10-28
Applicant: HISAMITSU PHARMACEUTICAL CO
Inventor: SATO HIDEJI , YAMAGUCHI HISASHI , NOZAWA ITSUKI , MAEDA HIROYUKI
IPC: A61K9/70
Abstract: PURPOSE:To obtain an apparatus for percutaneous treatment capable of accurately and surely feeding a prescribed amount of a medicine to a lesion part because of being free from loss of the medicine accompanied by removal of release liner in using. CONSTITUTION:A porous material constituting a medicine release material layer 3 for releasing a medicine from a medicine storage tank 2 to skin is subjected to coating treatment or impregnation treatment with a nonionic surfactant.
-
7.
公开(公告)号:JP2003201254A
公开(公告)日:2003-07-18
申请号:JP2001399314
申请日:2001-12-28
Applicant: HISAMITSU PHARMACEUTICAL CO
Inventor: SUZUKI MANZO , KAMIMURA KENGO , GOTO TAKESHI , TERAHARA TAKAAKI , MORI KENJI , HIGO SHIGETO , SATO HIDEJI
IPC: A61K45/06 , A61K31/135 , A61K31/485 , A61P25/04 , A61P43/00
Abstract: PROBLEM TO BE SOLVED: To provide a preparation avoiding adverse effect of an analgesic and an analgesic activity-enhancing agent and having continuous analgesic effect and to provide use thereof. SOLUTION: This preparation is used for enhancing analgesic effect of the analgesic and comprises an analgesic activity-enhancing agent and maintains a stationary blood concentration of the analgesic activity-enhancing agent within the range of 10-150 ng/ml. COPYRIGHT: (C)2003,JPO
-
公开(公告)号:JP2003137773A
公开(公告)日:2003-05-14
申请号:JP2001335334
申请日:2001-10-31
Applicant: HISAMITSU PHARMACEUTICAL CO
Inventor: TATEISHI TETSUO , HIGO SHIGETO , SATO HIDEJI
Abstract: PROBLEM TO BE SOLVED: To provide a readily attachable patch excellent in softness, not causing curling phenomenon, excellent in adhesiveness and feelings upon use and having sufficient skin-through property of a medicine, because absorption of the medicine to the support does not occur. SOLUTION: This patch has a laminated support obtained by laminating a knitted fabric on one surface of a polyester film and an adhesive layer containing a medicine and laminated to the other surface of the polyester film. In the patch, the knitted fabric has 0.1 kg/5 cm to 20 kg/5 cm 30% modulus in the vertical direction and =2 ratio of the 30% modulus in the vertical direction to the 30% modulus in the horizontal direction.
-
公开(公告)号:JPH09163983A
公开(公告)日:1997-06-24
申请号:JP23112496
申请日:1996-08-30
Applicant: HISAMITSU PHARMACEUTICAL CO
Inventor: SUZUKI EIJI , YUDA KAZUHIRO , AKIYAMA KATSUHIKO , GOTO TAKESHI , SATO HIDEJI
Abstract: PROBLEM TO BE SOLVED: To extremely improve productivity of a useful substance such as an antibody, a vector for gene therapy, cytokinin, an antigen for vaccine, etc., by transducing an apoptosis inhibitory gene to an animal cell capable of producing a useful substance. SOLUTION: An apoptosis inhibitory gene such as bcl-2, BAG-1, Bcl-XL, Ad.Elb or CrmA is transduced to bcl-2 transduced COS-1 cell (FERM P-15,808) as an animal cell capable of producing a useful substance by an electroporation method. A selective pressure is applied to the system to select a gene-transduced cell, which is cultured in a medium to mass produce a useful substance such as various antibodies produced by a hybridoma, a virus vector for treating a gene, various recombinant protein such as a cytokine, e.g. interferon, an antigen substance for a vaccine, etc., in improved productivity.
-
公开(公告)号:JPH08208750A
公开(公告)日:1996-08-13
申请号:JP31706695
申请日:1995-11-13
Applicant: HISAMITSU PHARMACEUTICAL CO
Inventor: OKAYAMA MINENOBU , SATO HIDEJI
IPC: A61K31/785 , A61P3/06 , B01J41/14 , C08F20/34
Abstract: PURPOSE: To obtain a non-cross-linked anion exchange resin used as a cholesterol lowering agent reduced in side effects such as the feeling of abdominal inflation and obstipation, freed from conventional drawbacks that it absorbs fat-soluble vitamins and that the difficulty in taking it is considerably large, freed from the inconvenience that it must be suspended when it is taken and being easily taken in the form of tablets, granules, capsules, or the like. CONSTITUTION: An anion exchange resin comprising repeating units of the formula [wherein R1 is benzyl or 1-20 C alkyl; R2 and R3 are the same or different from each other and each 1-4 C lower alkyl; R4 is hydrogen or lower alkyl group. X is a physiologically acceptable counter ion; n is 1-3; and p is the average degree of polymerization and is 10-10000].
-
-
-
-
-
-
-
-
-